These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 28600954)

  • 1. High-throughput thermofluor-based assays for inhibitor screening of STAT SH2 domains.
    de Araujo ED; Manaswiyoungkul P; Israelian J; Park J; Yuen K; Farhangi S; Berger-Becvar A; Abu-Jazar L; Gunning PT
    J Pharm Biomed Anal; 2017 Sep; 143():159-167. PubMed ID: 28600954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of STAT1 and STAT3 specific inhibitors using comparative virtual screening and docking validation.
    Szelag M; Czerwoniec A; Wesoly J; Bluyssen HA
    PLoS One; 2015; 10(2):e0116688. PubMed ID: 25710482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A functional in vitro assay for screening inhibitors of STAT5B phosphorylation.
    de Araujo ED; Manaswiyoungkul P; Erdogan F; Qadree AK; Sina D; Tin G; Toutah K; Yuen K; Gunning PT
    J Pharm Biomed Anal; 2019 Jan; 162():60-65. PubMed ID: 30223143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-Wide Inhibition of Pro-atherogenic Gene Expression by Multi-STAT Targeting Compounds as a Novel Treatment Strategy of CVDs.
    Plens-Galaska M; Szelag M; Collado A; Marques P; Vallejo S; Ramos-González M; Wesoly J; Sanz MJ; Peiró C; Bluyssen HAR
    Front Immunol; 2018; 9():2141. PubMed ID: 30283459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative screening and validation as a novel tool to identify STAT-specific inhibitors.
    Szeląg M; Czerwoniec A; Wesoly J; Bluyssen HA
    Eur J Pharmacol; 2014 Oct; 740():417-20. PubMed ID: 25183399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-Based Multiplexed Assay for Identifying SH2 Domain Antagonists.
    Asai A; Takakuma K
    Methods Mol Biol; 2017; 1555():351-356. PubMed ID: 28092042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity.
    Szelag M; Sikorski K; Czerwoniec A; Szatkowska K; Wesoly J; Bluyssen HA
    Eur J Pharmacol; 2013 Nov; 720(1-3):38-48. PubMed ID: 24211327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring dual inhibitors for STAT1 and STAT5 receptors utilizing virtual screening and dynamics simulation validation.
    Raj U; Kumar H; Gupta S; Varadwaj PK
    J Biomol Struct Dyn; 2016 Oct; 34(10):2115-29. PubMed ID: 26471877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel multiplexed assay for identifying SH2 domain antagonists of STAT family proteins.
    Takakuma K; Ogo N; Uehara Y; Takahashi S; Miyoshi N; Asai A
    PLoS One; 2013; 8(8):e71646. PubMed ID: 23977103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A high-throughput assay for signal transducer and activator of transcription 5b based on fluorescence polarization.
    Müller J; Schust J; Berg T
    Anal Biochem; 2008 Apr; 375(2):249-54. PubMed ID: 18258175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in signal transducer and activator of transcription 3 (STAT3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization.
    Resetca D; Haftchenary S; Gunning PT; Wilson DJ
    J Biol Chem; 2014 Nov; 289(47):32538-47. PubMed ID: 25288792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors.
    Furtek SL; Matheson CJ; Backos DS; Reigan P
    Oncotarget; 2016 Nov; 7(47):77998-78008. PubMed ID: 27793003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitor Library Screening of SH2 Domains Through Denaturation-Based Assays.
    de Araujo ED; Orlova A; Ashraf QF; Moriggl R; Gunning PT
    Methods Mol Biol; 2023; 2705():213-223. PubMed ID: 37668976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of a high-throughput fluorescence polarization assay for STAT5B DNA binding domain-targeting inhibitors.
    Manaswiyoungkul P; Erdogan F; Olaoye OO; Cabral AD; de Araujo ED; Gunning PT
    J Pharm Biomed Anal; 2020 May; 184():113182. PubMed ID: 32113119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity.
    Page BD; Khoury H; Laister RC; Fletcher S; Vellozo M; Manzoli A; Yue P; Turkson J; Minden MD; Gunning PT
    J Med Chem; 2012 Feb; 55(3):1047-55. PubMed ID: 22148584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel high-throughput screening system for identifying STAT3-SH2 antagonists.
    Uehara Y; Mochizuki M; Matsuno K; Haino T; Asai A
    Biochem Biophys Res Commun; 2009 Mar; 380(3):627-31. PubMed ID: 19285012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STAT 3 as a target for cancer drug discovery.
    Costantino L; Barlocco D
    Curr Med Chem; 2008; 15(9):834-43. PubMed ID: 18473793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescence Polarization Screening Assays for Small Molecule Allosteric Modulators of ABL Kinase Function.
    Grover P; Shi H; Baumgartner M; Camacho CJ; Smithgall TE
    PLoS One; 2015; 10(7):e0133590. PubMed ID: 26222440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A High-Throughput Fluorescence Polarization-Based Assay for the SH2 Domain of STAT4.
    Berg A; Gräber M; Schmutzler S; Hoffmann R; Berg T
    Methods Protoc; 2022 Nov; 5(6):. PubMed ID: 36548135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SH2 domains of Stat1 and Stat2 mediate multiple interactions in the transduction of IFN-alpha signals.
    Gupta S; Yan H; Wong LH; Ralph S; Krolewski J; Schindler C
    EMBO J; 1996 Mar; 15(5):1075-84. PubMed ID: 8605877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.